New developments in IL-6 dependent biology and therapy: where do we stand and what are the options?

Bibliography

• AKIRA S, TAGA T, KISHIMOTO T: Interleukin-6 in biology and medicine. Adv. Immunol (1993) 54:1–78.
   PubMed Web of Science ®Google Scholar
• TAGA T, KISHIMOTO T: gp130 and the Interleukin-6 family of cytokines. Ann. Rev. Immunol. (1997) 15:797–819.
   PubMed Web of Science ®Google Scholar
• PETERS M, MULLER AM, ROSE JOHNS: Interleukin-6 andsoluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood (1998) 92:3495–3504.
   PubMed Web of Science ®Google Scholar
• NISHIMURA R, MORIYAMA K, YASUKAWA K, MUNDY GR, YONEDA T: Combination of interleukin-6 and soluble interleukin-6 receptors induces differentiation and activation of JAK-STAT and MAP kinase pathways in MG-63 human osteoblastic cells. J. Bone Miner Res. (1998) 13:777–785.
   PubMed Web of Science ®Google Scholar
• GAULDIE J, RICHARDS C, HARNISH D, LANSDORP P, BAUMANN H: Interferon beta 2/B-cell stimulatory factor Type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc. Natl Acad. Sci. USA (1987) 84:7251–7255.
   PubMed Web of Science ®Google Scholar
• SUEMATSU S, MATSUSAKA T, MATSUDA T et al.: Genera-tion of plasmacytomas with the chromosomal translo-cation 012;15) in interleukin 6 transgenic mice. Proc. Nati Acad. Sci. USA (1992) 89:232–235.
   PubMed Web of Science ®Google Scholar
• BRANDT SJ, BODINE DM, DUNBA CE, NIENHUIS AW:Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J. Clin. Invest. (1990) 86:592–599.
   PubMed Web of Science ®Google Scholar
• HORII Y, MURAGUCHI A, IWANO M et al: Involvement ofinterleukin-6 in mesangial proliferative glomeru-lonephritis. j Immunol. (1989) 143:3949–3955.
   PubMed Web of Science ®Google Scholar
• JILKA RL, HANGOC G, GIRASOLE G et al: Increasedosteoclast development after estrogen loss: Mediation by interleukin-6. Science (1992) 257:88–91.
   PubMed Web of Science ®Google Scholar
• STRASSMANN G, FONG M, KENNEY JS, CHAIM OJ: Mechanisms of experimental cancer cachexia. Interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia. j Clin. Invest. (1992) 89:1681–1684.
   Google Scholar
• HERMANN E, FLEISCHER B, MAYET W-J, PORALLA T, MEYER ZUM BOSCHENFELDE K-H: Correlation of synovial fluid interleukin 6 (IL-6) activities with IgG concentrations in patients with inflammatory joint disease and osteoarthritis. Clin. Exp. Rheumatol. (1989) 7:411–414.
   PubMed Web of Science ®Google Scholar
• HACK CE, DE GROOT ER, FELT-BERSMA RJF: Increasedplasma levels of interleukin-6 in sepsis. Blood (1989) 74: 1704-1710.
   Google Scholar
• WAAGE A, BRANDTZAEG P, HALSTENSEN A, KIERULF P,ESPEVIK T: The complex pattern of cytokines in serum from patients with meningococcal septic shock. J. Exp. Merl. (1989) 169:333–338.
   PubMed Web of Science ®Google Scholar
• POLI G, BRESSLER P, KINTER A et al: Interleukin 6induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional mechanisms. J. Exp. Med. (1990) 1 72:151–158.
   Google Scholar
• HONDA M, YAMAMOTO S, CHENG M et al.: Humansolulbe IL-6 receptor: its detection and enhanced release by HIV infection. J. Immunol. (1 99 2) 148:2175-2180.
   Google Scholar
• WARD LD, HOWLETT GJ, DISCOLO G eta].: High affinityinterleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp-130. J. Biol Chem. (1994) 269:23286–23289.
   Google Scholar
• PAONESSA G, GRAZIANI R, DE SERIO A et al: Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signalling. EMBO J. (1995) 14:1942–1951.
   PubMed Web of Science ®Google Scholar
• GROTZINGER J, KURAPKAT G, WOLLMER A, KALAI M,ROSE-JOHN S: The family of the IL-6-type cytokines: specificity and promiscuity of the receptor complexes. Proteins: Structure, Function, and Genetics (1997) 27:96–109.
   PubMed Web of Science ®Google Scholar
• MCDONALD NQ, PANAYOTATOS N, HENDRICKSON WA:Crystal structure of dimeric human ciliary neurotrophic factor determined by MAD phasing. EMBO J. (1995) 14:2689–2699.
   PubMed Web of Science ®Google Scholar
• PANAYOTATOS N, RADZIEJEWSKA E, ACHESON A et al:Localizition of functional receptor epitopes on the structure of ciliary neurotrophic factor indicates a conserved, function-related epitope topography among helical cytokines. J. Biol. Chem. (1995) 270:14007–14014.
   PubMed Web of Science ®Google Scholar
• GROTZINGER J, KERNEBECK T, KALLEN K-J, ROSE-JOHNS: IL-6 type Cytokine Receptor Complexes: Hexamer or Tetramer or Both? Biol. Chem. (1999) (In Press).
   Google Scholar
• •Suggests a new model of the IL-6 receptor complex assuming that the active complex is a tetramer, whereas an inactive hexameric complex is assembled at higher concen-trations of IL–6.
   Google Scholar
• KROTTGEN A, ROSE-JOHN S, MOLLER C et al: Structure-function analysis of human interleukin-6. Evidence for the involvement of the carboxy-terminus in function. FEBS Lett. (1990) 262:323–326.
   PubMed Web of Science ®Google Scholar
• KROTTGEN A, ROSE-JOHNS, DUFHUES G et al: The three carboxy-terminal amino acids of human interleukin-6 are essential for its biological activity. FEBS Lett. (1990) 273:95–98.
   PubMed Web of Science ®Google Scholar
• LOTTICKEN C, KROTTGEN A, MOLLER C, HEINRICH PC,ROSE-JOHN S: Evidence for the importance of a positive charge and an alpha-helical structure of the C-terminus for biological activity of human IL-6. FEBS Lett. (1991) 282:265–267.
   PubMed Web of Science ®Google Scholar
• BRAKENHOFF JP, HART M, AARDEN LA: Analysis of human IL-6 mutants expressed in Escherichia coli. Biologic activities are not affected by deletion of amino acids 1-28.1 Immunol. (1989) 143:1175–1182.
   Google Scholar
• BRAKENHOFF JP, HART M, DE GROOT ER, DI PADOVA F, AARDEN LA: Structure-function analysis of human IL-6. Epitope mapping of neutralizing monoclonal anti-bodies with amino- and carboxyl-terminal deletion mutants. J. Immunol. (1990) 145:561–568.
   Google Scholar
• VAN DAM M, MOLLBERG J, SCHOOLTINK H et al.: Structure-function analysis of interleukin-6 utilizing human/murine chimeric molecules. Involvement of two separate domains in receptor binding. J. Biol Chem. (1993) 268:15285–15290.
   Google Scholar
• EHLERS M, GROTZINGER J, DEHON F eta].: Identification of two novel regions of human IL-6 responsible for receptor binding and signal transduction. J. Immunol (1994) 153:1744–1753.
   Google Scholar
• KALLEN K-J, GROTZINGER J, LELIEVRE E et al.: Receptor recognition sites of cytokines are organized as exchangeable modules: transfer of the LIFR binding site from CNTF to I1-6. J. Biol. Chem. (1999) 274:11859–11867.
   PubMed Web of Science ®Google Scholar
• ••Demonstrates that it is possible to generate designercytokines with new receptor specifities by assuming the existence of modular receptor recognition sites on cytokines.
   Google Scholar
• YAWATA H, YASUKAWA K, NATSUKA S eta].: Structure- function analysis of human11-6 receptor: dissociation of amino acid residues required for 11-6-binding and for 11–6 signal transduction through gp130. EMBO J. (1993) 12:1705–1712.
   Google Scholar
• KALAI M, MONTERO-JULIAN FA, GROTZINGER J et al.: Participation of two Ser-Ser-Phe-Tyr repeats in interleukin-6 (IL-6)- binding sites of the human IL-6 receptor. Eur. j Biochem. (1996) 238:714–723.
   PubMedGoogle Scholar
• HORSTEN U, SCHMITZ-VAN DE LEUR H, MOLLBERG J, HEINRICH PC, ROSE-JOHN S: The membrane distal half of gp130 is responsible for the formation of a ternary complex with IL-6 and the IL-6 receptor. FEBS Lett. (1995) 360:43–46.
   PubMed Web of Science ®Google Scholar
• HORSTEN U, MULLER NEWEN G, GERHARTZ C et al:Molecular modeling-guided mutagenesis of the extracellular part of gp130 leads to the identification of contact sites in the interleukin-6 (IL-6),IL-6 receptor.gp130 complex. J. Biol. Chem. (1997) 272:23748–23757.
   Google Scholar
• WELLS JA: Hematopoietic receptor complexes. Ann.Rev. Biochem. (1996) 65:609–634.
   PubMed Web of Science ®Google Scholar
• SAVINO R, LAHM A, SALVATI AL et al.: Generation of interleukin-6 receptor antagonists by molecular-modeling guided mutagenesis of residues important for gp130 activation. EMBO J (1994) 13:1357–1367.
   PubMed Web of Science ®Google Scholar
• SAVINO R, CIAPPONI L, LAHM A et al.: Rational design of a receptor super-antagonist of human interleukin-6. EMBO J (1994) 13:5863–5870.
   PubMed Web of Science ®Google Scholar
• MOLLBERG J, SCHOOLTINK H, STOYAN T et al.: The soluble interleukin-6 receptor is generated by shedding. Eur. J. Immunol. (1993) 23:473–480.
   PubMed Web of Science ®Google Scholar
• MOLLBERG J, OBERTHUR W, LOTTSPEICH F et al.: The soluble human IL-6 receptor. Mutational characteriza-tion of the proteolytic cleavage site. J. Immunol. (1994) 152:4958–4968.
   Google Scholar
• TAGA T, HIBI M, HIRATA Y et al.: Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell (1989) 58:573–581.
   PubMed Web of Science ®Google Scholar
• MACKIEWICZ A, SCHOOLTINK H, HEINRICH PC, ROSE-JOHN S: Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J. Immunol. (1992) 149:2021–2027.
   PubMed Web of Science ®Google Scholar
• ROSE-JOHN S, HEINRICH PC: Soluble receptors for cytokines and growth factors: generation and biological function. Biochem. J. (1994) 300:281–290.
   PubMed Web of Science ®Google Scholar
• PETERS M, JACOBS S, EHLERS M et al.: The function of the soluble interleukin 6 (11-6) receptor in vivo: sensitiza-tion of human soluble 11-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J. Exp. Med. (1996) 183:1399–406.
   PubMed Web of Science ®Google Scholar
• SUI X, TSUJI K, TANAKA R et al.: gp130 and c-Kit signal-ings synergize for ex vivo expansion of human primitive hemopoietic progenitor cells. Proc. Natl. Acad. Sci. USA (1995) 92:2859–2863.
   PubMed Web of Science ®Google Scholar
• PETERS, M, SCHIRMACHER P, GOLDSCHMITT J et al.: Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice. J. Exp. Med. (1997) 185:755–766.
   PubMed Web of Science ®Google Scholar
• •Reports a very unexpected finding, namely that hepatic overexpression of IL-6 and soluble IL-6R vastly increases extramedullary haematopoiesis.
   Google Scholar
• HIROTA H, KIYAMA H, KISHIMOTO T, TAGA T: Acceler- ated nerve regeneration in mice by upregulated expression of interleukin (IL) 6 and11-6 receptor after trauma [see comments]. J. Exp. Med. (1996) 183:2627–2634.
   PubMed Web of Science ®Google Scholar
• MARZ P, HERGET T, LANG E, OTTEN U, ROSE-JOHN S: Activation of gp130 by 11-6/soluble IL-6 receptor induces neuronal differentiation. Eur. J. Neurosci. (1997) 9:2765–2773.
   PubMed Web of Science ®Google Scholar
• MARZ P, CHENG J-C, GADIENT RA et al.: Sympathetic neurons can produce and respond to Interleukin-6. Proc. Natl. Acad. Sci. USA (1998) 95:3251–3256.
   PubMed Web of Science ®Google Scholar
• THIER M, MARZ P, OTTEN U, WETS J, ROSE-JOHN S: Interleukin-6 (IL-6) supports survival of sensory neurons: autocrine trophic effects of 11-6 and soluble 11-6 receptor and enhanced activity of an11-6 designer cytokine. j Neurosci. Res. (1999) 55:411–422.
   PubMed Web of Science ®Google Scholar
• MARZ P, HEESE K, DIMITRIADES-SCHMUTZ B, ROSE-JOHN S, OTTEN U: Role of interleukin-6 and soluble I1-6 receptor in region specific induction of astrocytic differentiation and neurotrophin expres-sion. Glia (1999) 26:191–200.
   PubMed Web of Science ®Google Scholar
• SCHAFER KH, MESTRES P, MARZ P, ROSE-JOHN S: The IL-6/sIL-6R fusion protein promotes neurite outgrowth and neuronal survival in cultured enteric neurons. J. Interferon Cytokine Res. (1999) (19:527–532.
   Google Scholar
• MARZ P, OTTEN U, ROSE-JOHN S: Neuronal activities of 11–6 type cytokines often depend on soluble cytokine receptors. Eur. j Neurosci. (1999) (In Press).
   Google Scholar
• KALLEN K-J, MEYER ZUM BOSCHENFELDE KH, ROSE-JOHN S: The therapeutic potential of interleukin-6 hyperagonists and antagonists. Exp. Opin. Invest. Drugs (1997) 6:237–266.
   PubMedGoogle Scholar
• HIRANO T, YASUKAWA K, HARADA H et al.: Complemen-tary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature (1986) 324:73–76.
   PubMed Web of Science ®Google Scholar
• XU GY, YU HA, HONG J et al.: Solution structure of recombinant human interleukin-6. J. Mol Biol. (1997) 268:468–481.
   PubMed Web of Science ®Google Scholar
• SOMERS W, STAHL M, SEEHRA JS: 1.9 A crystal structureof interleukin 6: implications for a novel mode of receptor dimerization and signaling. EMBO J. (1997) 16:989–997.
   Google Scholar
• BAZAN JF: Haemopoietic receptors and helical cytokines. Immunol. Today (1990) 11:350–354.
   PubMedGoogle Scholar
• BRAKENHOFF JP, DE HON FD, FONTAINE V et al.: Development of a human interleukin-6 receptor antagonist. J. Biol. Chem. (1994) 269:86–93.
   PubMed Web of Science ®Google Scholar
• DE HON FD, EHLERS M, ROSE-JOHN S et al.: Develop-ment of an interleukin (IL) 6 receptor antagonist that inhibits 11-6-dependent growth of human myeloma cells. J. Exp. Med. (1994) 180:2395–2400.
   PubMed Web of Science ®Google Scholar
• EHLERS M, DE HON FD, BOS HK et al.: Combining two mutations of human interleukin-6 that affect gp130 activation results in a potent interleukin-6 receptor antagonist on human myeloma cells. J. Biol. Chem. (1995) 270:8158–8163.
   PubMed Web of Science ®Google Scholar
• SPORENO E, SAVINO R, CIAPPONI L et al.: Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells. Blood (1996) 87:4510–4519.
   PubMed Web of Science ®Google Scholar
• FISCHER M, GOLDSCHMITT J, PESCHEL C et al: A designer cytokine with high activity on human hematopoietic progenitor cells. Nature Biotechnol. (1997) 15:142–145.
   PubMed Web of Science ®Google Scholar
• ••Shows that fusing the soluble IL-6R to IL-6 generates adesigner cytokine that is an extremely strong activator of gp130.
   Google Scholar
• EAVES C, MILLER C, CONNEALLY E et al.: Introduction tostem cell biology in vitro: threshold to the future. Ann. NY Acad. Sci. (1999) 872:1–8.
   PubMed Web of Science ®Google Scholar
• FUJISAKI T, BERGER MG, ROSE-JOHN S, EAVES C: Rapiddifferentiation of a rare subset of adult human lin-Cd34-Cd38- cells stimulated by multiple growth factors in vitro. Blood (1999) In Press.
   Google Scholar
• ISHIBASHI T, KIMURA H, SHIKAMA Y et al: Interleukin-6is a potent thrombopoietic factor in vivo in mice. Blood (1989) 74:1241–1244.
   PubMed Web of Science ®Google Scholar
• PORGADOR A, TZEHOVAL E, KATZ A, VADAI E, REVEL M,FELDMAN M, EISENBACH L: Interleukin 6 gene transfec-tion into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunothera-peutic competence against parental metastatic cells. Cancer Res. (1992) 52:3679–3686.
   PubMed Web of Science ®Google Scholar
• PFLANZ S, TACKEN I, GROTZINGER J, JACQUES Y,DAHMEN H, HEINRICH PCM-N, G: A fusion protein of interleukin-11 and soluble interleukin-11 receptor acts as superagonist on cells expressing gp130. FEBS Lett. (1999) 450:117–122.
   PubMed Web of Science ®Google Scholar
• ZHANG XG, GU JJ, LU ZY et al: Ciliary neurotropicfactor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. J. Exp. Med. (1994) 179:1337–1342.
   PubMed Web of Science ®Google Scholar
• KISHIMOTO T, TANAKA T, YOSHIDA K, AKIRA S, TAGA T:Cytokine signal transduction through a homo- or heterodimer of gp130. Ann. NY Acad. Sci. (1995) 766:224–234.
   PubMed Web of Science ®Google Scholar
• RENNÉ C, KALLEN K-J, MeLLBERG J, JOSTOCK T,GROTZINGER J, ROSE-JOHN S: A new type of cytokine receptor antagonist directly targeting gp130. J. Biol. Chem. (1998) 273:27213–27219.
   PubMed Web of Science ®Google Scholar
• BATAILLE R, BARLOGIE B, LU ZY et al: Biologic effects ofanti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood (1995) 86:685–691.
   PubMed Web of Science ®Google Scholar
• MONTERO JULIAN FA, KLEIN B, GAUTHEROT E, BRAILLYH: Pharmacokinetic study of anti-interleukin-6 (11-6) therapy with monoclonal antibodies: enhancement of 11-6 clearance by cocktails of anti-IL-6 antibodies. Blood (1995) 85:917–924.
   PubMed Web of Science ®Google Scholar
• KLEIN B, WIJDENES J, ZHANG XG et al.: Murineanti-interleukin-6 monoclonal therapy for a patient with plasma cell leukemia. Blood (1991) 78:1198–1204.
   PubMed Web of Science ®Google Scholar
• WENDLING D, RACADOT E, WIJDENES J: Treatment ofsevere rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J. Rheumatol (1993) 20:259–262.
   PubMed Web of Science ®Google Scholar
• LU ZY, BRAILLY H, WIJDENES J, BATAILLE R, ROSSI JF,KLEIN B: Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood (1995) 86:3123–3131.
   PubMed Web of Science ®Google Scholar
• HIRATA Y, TAGA T, HIBI M, NAKANO N, HIRANO T, KISHIMOTO T: Characterization of IL-6 receptor expression by monoclonal and polyclonal antibodies. Immunol. (1989) 143:2900–2906.
   Web of Science ®Google Scholar
• SATO K, TSUCHIYA M, SALDANHA J et al.: Reshaping ahuman antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. (1993) 53:851–856.
   PubMed Web of Science ®Google Scholar
• TAKAGI N, MIHARA M, MORIYA Y et al.: Blockage ofinterleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum. (1998) 41:2117–2121.
   PubMed Web of Science ®Google Scholar
• NISHIMOTO N, KISHIMOTO T, YOSHIZAKI K: Anticyto-kine therapy in autoimmune diseases. Intern. Med. (1999) 38:178–182.
   PubMed Web of Science ®Google Scholar
• NISSIM A, HOOGENBOOM HR, TOMLINSON IM et al.:Antibody fragments from a 'single pot' phage display library as immunochemical reagents. EMBO J. (1994) 13:692–698.
   PubMed Web of Science ®Google Scholar
• KREBS B, GRIIFIN H, WINTER G, ROSE-JOHNS: Recombi-nant human scFv antibodies recognizing human interleukin-6: specific targeting of cytokine secreting cells. J. Biol. Chem. (1998) 273:2858–2865.
   PubMed Web of Science ®Google Scholar
• •Shows that bispecific antibodies can be tailored to recognize and induce killing by T-cells of IL-6 secreting cells.
   Google Scholar
• ASSENMACHER M, SCHEFFOLD A, SCHMITZ J, SEGURACHECA JA, MILTENYI S, RADBRUCH A: Specific expres-sion of surface interferon-gamma on interferon-gamma producing T cells from mouse and man. Eur. J. Immunol. (1996) 26:263–267.
   PubMed Web of Science ®Google Scholar
• KREBS B, ACKERMANN B, ROSE-JOHN S: Specifictargeting of cytokine secreting cells: a bispecific diabody recognizing human 11-6 and CD3 induces t-cell mediated killing. J. Interferon Cytokine Res. (1998) 18:783–791.
   PubMed Web of Science ®Google Scholar
• DRAKESMITH H, O'NEIL D, SCHNEIDER SC eta].: In vivopriming of T cells against cryptic determinants by dendritic cells exposed to interleukin 6 and native antigen. Proc. Natl. Acad. Sci. USA (1998) 95:14903–14908.
   Google Scholar
• •A seminal, thought-provoking paper that sheds light on the relation between high IL-6 levels and autoimmune disease.
   Google Scholar
• GREEN RM, WHITING JF, ROSENBLUTH AB, BEIER D, GOLLAN JL: Interleukin-6 inhibits hepatocyte taurocholate uptake and sodium-potassium-adenosinetriphosphatase activity. Am. J. Physic)]. (1994) 267:G1094–100.
   PubMed Web of Science ®Google Scholar
• HOUSSIAU FA, DEVOGELAER JP, VAN DAMME J, DE DEUXCHAISNES CN, VAN SNICK J: Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. (1988) 31:784–788.
   PubMed Web of Science ®Google Scholar
• MAUBACH K, FOEY AD, HALL ND: Impaired activity of thiol-dependent ATPases in rheumatoid mononuclear cell membranes. Agents Actions (1993) 39:C107–109.
   PubMedGoogle Scholar
• THOMAS R, LIPSKY PE: Could endogenous self-peptides presented by dendritic cells initiate rheumatoid arthritis? Immunol. Today (1996) 17:559–564.
   Google Scholar
• FRANKE S, HERRMANN D, HEIN G, MULLER A, STEIN G: Interleukin-6, soluble interleukin-2-receptor and soluble interleukin-6-receptor in sera of patients with rheumatoid arthritis: influences of disease activity and drug therapy. Eur. J. Med. Res. (1997) 2:401–406.
   PubMedGoogle Scholar
• STRAUB RH, MULLER LADNER U, LICHTINGER T, SCHOLMERICH J, MENNINGER H, LANG B: Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs. Br. J. Rheumatol. (1997) 36:1298–1303.
   PubMedGoogle Scholar
• MIYAZAWA K, MORI A, MIYATA H, AKAHANE M, AJISAWA Y, OKUDAIRA H: Regulation of interleukin-lbeta-induced interleukin-6 gene expression in human fibroblast-like synoviocytes by p38 mitogen-activated protein kinase. J. Biol. Chem. (1998) 273:24832–24838.
   PubMed Web of Science ®Google Scholar
• CHOMARAT P, RISSOAN MC, PIN JJ, BANCHEREAU J, MIOSSEC P. Contribution of IL-1, CD14, and CD13 in the increased IL-6 production induced by in vitro monocyte-synoviocyte interactions. J. Immunol. (1995) 155:3645–3652.
   Google Scholar
• KOTAKE S, SATO K, KIM KJ et al.: Interleukin-6 andsoluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J. Bone Miner Res. (1996) 11:88–95.
   PubMed Web of Science ®Google Scholar
• GOUGH A, SAMBROOK P, DEVLIN J et al.: Osteoclasticactivation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis [see comments]. J. Rheumatol. (1998) 25:1282–1289.
   PubMed Web of Science ®Google Scholar
• ALONZI T, FATTORI E, LAZZARO D et al.: Interleukin 6 isrequired for the development of collagen-induced arthritis. J. Exp. Med. (1998) 187:461–468.
   PubMed Web of Science ®Google Scholar
• •Shows that IL-6 deficiency prevents collagen-induced, but not TNF-a induced arthritis.
   Google Scholar
• OHSHIMA S, SAEKI Y, MIMA T et al.: Interleukin 6 plays akey role in the development of antigen-induced arthritis. Proc. Natl. Acad. Sci. USA (1998) 95:8222–8226.
   PubMed Web of Science ®Google Scholar
• KOZAWA O, SUZUKI A, KAIDA T, TOKUDA H, UEMATSUT: Tumor necrosis factor-a autoregulates interleukin-6 synthesis via activation of protein kinase C. J. Biol. Chem. (1997) 272:25099–25104.
   PubMed Web of Science ®Google Scholar
• MACHELON V, NOME F, DURAND-GASSELIN I, EMILIE D Tumor necrosis factor-alpha induces interleukin-6 mRNA and protein in human granulosa luteinizing cells via protein tyrosine kinase without involving ceramide. Mol. Cell Endocrinol. (1997) 126:173–184.
   PubMed Web of Science ®Google Scholar
• PIERRE P, MELLMAN I: Developmental regulation ofinvariant chain proteolysis controls MHC class II trafficking in mouse dendritic cells. Cell (1998) 93:1135–1145.
   PubMed Web of Science ®Google Scholar
• SILACCI P, DAYER J-M, DESGEORGES A, PETER R,MANUEDDU C, GUERNE P-A: Interleukin (IL)-6 and its soluble receptor induce TIMP-1 expression in synovio-cytes and chondrocytes, and block IL-1 induced collagenolytic acitivity. J. Biol. Chem. (1998) 273:13625–13629.
   PubMed Web of Science ®Google Scholar
• RAY A, SCHATTEN H, RAY BK: Activation of Spl and its functional co-operation with serum amyloid-activating sequence binding factor in synoviocyte cells trigger synergistic action of interleukin-1 and interleukin-6 in serum amyloid gene expression. J. Biol. Chem. (1999) 274:4300–4308.
   PubMed Web of Science ®Google Scholar
• KEUL R, HEINRICH PC, MULLER-NEWEN G, MULLER K, WOO P: A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine (1998) 10:729–734.
   PubMed Web of Science ®Google Scholar
• DEBENEDETTI F, MASSA M, PIGNATTI P, ALBANI S, NOVICK D, MARTINI A: Serum soluble interleukin-6(IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J. Clin. Invest. (1994) 93:2114–2119.
   PubMed Web of Science ®Google Scholar
• FISHMAN D, FAULDS G, JEFFERY R et al.: The effect of novel polymorphisms in the interleukin-6 01-0 gene on 11-6 transcription and plasma 11-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. (1998) 102:1369–1376.
   PubMed Web of Science ®Google Scholar
• NAUMANN M, WESSLER S, BARTSCH C, WIELAND B, MEYER T: Neisseria gonorrhea epithelial cell interac-tion leads to activation of the transcription factor nuclear factor KB and activator protein 1 and the induction of inflammatory cytokines. J. Exp. Med. (1997) 186:247–258.
   PubMed Web of Science ®Google Scholar
• •Points to a possible mechanism of infectious arthritis.
   Google Scholar
• KAWAGUCHI, Y, HARA M, WRIGHT TM: Endogenous IL-1_ from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J. Clin. Invest. (1999) 103:1253–1260.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, BAUMGARTNER SW, SCHIFF MH: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. New Engl. J. Med. (1997) 337:141–147.
   PubMed Web of Science ®Google Scholar
• •A biotechnological success story.
   Google Scholar
• MATSUNO H, SAWAI T, NEZUKA T et al.: Treatment of rheumatoid synovitis with anti-reshaping human interleukin-6 receptor monoclonal antibody: use of rheumatoid arthritis tissue implants in the SCID mouse model. Arthritis Rheum. (1998) 41:2014–2021.
   PubMed Web of Science ®Google Scholar
• SUGIYAMA E, SUZUKI H, TUNRU IS, YAMASHITA N, HORI T, KOBAYASHI M: FK506, an immunosuppressant, partially inhibits interleukin 6 production by adherent rheumatoid synovial cells. J. Rheumatol. (1994) 21:1597–1601.
   PubMed Web of Science ®Google Scholar
• CRILLY A, MCINNES TB, CAPELL HA, MADHOK R: The effect of azathioprine on serum levels of interleukin 6 and soluble interleukin 2 receptor. Scand. J. Rheumatol. (1994) 23:87–91.
   PubMed Web of Science ®Google Scholar
• CRILLY A, MCINNESS TB, MCDONALD AG, WATSON J, CAPELL HA, MADHOK R: Interleukin 6 (IL-6) and soluble 11-2 receptor levels in patients with rheuma-toid arthritis treated with low dose oral methotrexate. Rheumatol. (1995) 22:224–226.
   Web of Science ®Google Scholar
• CRILLY A, KOLTA S, DOUGADOS M, STURROCK RD, AMOR B, CAPELL HA, MADHOK R: Effect of cyclosporin A on interleukin-6 and soluble interleukin-2 receptor in patients with rheumatoid arthritis. Ann. Rheum. Dis. (1995) 54:137–139.
   PubMed Web of Science ®Google Scholar
• CRILLY A, CAPELL HA, WATSON J, MADHOK R: The effect of auranofin and sulphasalazine therapy on circulating levels of interleukin 6 in rheumatoid arthritis patients. Clin. Rheumatol. (1995) 14:561–565.
   PubMed Web of Science ®Google Scholar
• YIN M-J, YAMAMOTO Y, GAYNOR RB: The anti-inflammatory agents aspirin and salicylate inhibit the activity of Ix13 kinase-p. Nature (1998) 396:77–80.
   PubMed Web of Science ®Google Scholar
• LIBERMAN TA, BALTIMORE D: Activation of interleukin-6 gene expression through NF-KB transcription factor. Mol. Cell Biol. (1990) 10:2327–2334.
   PubMed Web of Science ®Google Scholar
• EITNER F, WESTERHUIS R, BURG M et al: Role of interleukin-6 in mediating mesangial cell prolifera-tion and matrix production in vivo. Kidney Int. (1997) 51:69–78.
   PubMed Web of Science ®Google Scholar
• KARKAR AM, SMITH J, TAM FW, PUSEY CD, REES AJ: Abrogation of glomerular injury in nephrotoxic nephritis by continuous infusion of interleukin-6. Kidney Int. (1997) 52:1313–1320.
   PubMed Web of Science ®Google Scholar
• SOTO HM, PARRA G, RODRIGUEZ ITRUBE B: Circulating levels of cytokines in poststreptococcal glomeru-lonephritis. Gun. Nephrol (1997) 47:6–12.
   Web of Science ®Google Scholar
• FINCK BK, CHAN B, WOFSY D: Interleukin 6 promotes murine lupus in NZB/NZW Fl mice. J. Clin. Invest. (1994) 94:585–591.
   PubMed Web of Science ®Google Scholar
• MIHARA M, TAKAGI N, TAKEDA Y, OHSUGI Y: 11-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin. Exp. Immunol. (1998) 112:397–402.
   PubMed Web of Science ®Google Scholar
• RICHARDS HB, SATOH M, SHAW M, LIBERT C, POLI V, REEVES WH: Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J. Exp. Med. (1998) 188:985–990.
   PubMed Web of Science ®Google Scholar
• •Shows that generation of antiDNA antibodies depends on IL-6, but that they are not causally involved in the genesis of lupus nephritis.
   Google Scholar
• NENG LAI K, LEUNG JC, BIK LAI K, LI PK, LAI CK: Anti-DNA autoantibodies stimulate the release of interleukin-1 and interleukin-6 from endothelial cells. Pathol. (1996) 178:451–457.
   Web of Science ®Google Scholar
• ROMANO M, SIRONI M, TONIATTI C et al: Role of 11-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity (1997) 6:315–325.
   PubMed Web of Science ®Google Scholar
• ••The soluble IL-6R renders endothelial cells responsive toIL-6 and causes them to express leucocyte attracting chemokines.
   Google Scholar
• MODUR V, LI Y, ZIMMERMAN GA, PRESCOTT SM, MCINTYRE TM: Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. J. Clin. Invest. (1997) 100:2752–2756.
   PubMed Web of Science ®Google Scholar
• •Neutrophils may be the source for soluble IL-6R that makes endothelial cells responsive to IL–6.
   Google Scholar
• MODUR V, FELDHAUS MJ, WEYRICH AS eta].: Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflam-matory cytokines and adhesion molecules. J. Clin. Invest. (1997) 100:158–68.
   Google Scholar
• HOOPER WC, PHILLIPS DJ, EVATT BL: Endothelial cell protein S synthesis is upregulated by the complex of 11-6 and soluble 11-6 receptor. Thromb. Haemost. (1997) 77:1014–1019.
   PubMed Web of Science ®Google Scholar
• MAIONE D, DI CARLO E, LI W eta].: Coexpression of 11–6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBO J (1998) 17:5588–5597.
   Google Scholar
• ••An excellent study on early effects of hepatic overexpres-sion of IL-6 and soluble IL-6R in mice. Shows that coexpres-sion of IL-6 and soluble IL-6R lead to endothelitis and hepatoma.
   Google Scholar
• WAGNER AD, GORONZY JJ, WEYAND CM: Functional profile of tissue-infiltrating and circulating CD68+ cells in giant cell arteritis. Evidence for two components of the disease. J. Clin. Invest. (1994) 94:1134–1140.
   PubMed Web of Science ®Google Scholar
• OKUDA Y, SAKODA S, BERNARD CC et al.: 11-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein. Int. Immunol. (1998) 10:703–708.
   PubMed Web of Science ®Google Scholar
• EUGSTER HP, FRET K, KOPF M, LASSMANN H, FONTANA A: 11-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomye-litis. Eur. j Immunol. (1998) 28:2178–2187.
   PubMed Web of Science ®Google Scholar
• MENDEL I, KATZ A, KOZAK N, BEN NUN A, REVEL M: Interleukin-6 functions in autoimmune encephalo-myelitis: a study in gene-targeted mice. Eur. J. Immunol (1998) 28:1727–1737.
   PubMed Web of Science ®Google Scholar
• SAMOILOVA EB, HORTON JL, HILLIARD B, LIU TS, CHEN Y: 11-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of 11-6 in the activation and differentiation of autoreactive T cells. J. Immunol. (1998) 161:6480–6486.
   PubMed Web of Science ®Google Scholar
• •Shows that protection against autoimmune disease in IL-6 deficient mice is due to a defect in T-cell differentiation.
   Google Scholar
• VOLLMER P, WALEV I, ROSE-JOHN S, BHAKDI S: Novel pathogenic mechanism of microbial metalloprote-inases: liberation of membrane-anchored molecules in biologically active form exemplified by studies with the human interleukin-6 receptor. Infect. Immun. (1996) 64:3646–3651.
   PubMed Web of Science ®Google Scholar
• GROTTRUP WOLFERS E, MOELLER J, KARBACH U, MULLER LISSNER S, ENDRES S: Elevated cell-associated levels of interleukin lbeta and interleukin 6 in inflamed mucosa of inflammatory bowel disease. Eur. Clin. Invest. (1996) 26:115–122.
   PubMed Web of Science ®Google Scholar
• REIMUND JM, WITTERSHEIM C, DUMONT S et al.: Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J. Clin. Immunol. (1996) 16:144–150.
   PubMed Web of Science ®Google Scholar
• ARAI F, TAKASHI T, MATSUSHIMA K, ASAKURA H: Mucosal expression of interleukin-6 and interleukin-8 messenger RNA in ulcerative colitis and in Crohn's disease. Dig. Dis. Sci. (1998) 43:2071–2079.
   PubMed Web of Science ®Google Scholar
• HOLUB MC, MAKO E, DEVAY T et al.: Increased interleukin-6 levels, interleukin-6 receptor and gp130 expression in peripheral lymphocytes of patients with inflammatory bowel disease. Scand. J. Gastroen-terol. Suppl. (1998) 228:47–50.
   Google Scholar
• POLLAK RD, KARMELI F, ELIAKIM R, ACKERMAN Z, TABB K, RACHMILEWITZ D: Femoral neck osteopenia in patients with inflammatory bowel disease. Am. J. Gastroenterol (1998) 93:1483–1490.
   PubMed Web of Science ®Google Scholar
• MITSUYAMA K, TOYONAGA A, SASAKI E et al: Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut (1995) 36:45–49.
   PubMed Web of Science ®Google Scholar
• NEURATH MF, PETTERSSON S, MEYER ZUM BeJSCHEN-FELDE K-H, STROBER W: Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-?B abrogates established experi-mental colitis in mice. Nature Med. (1996) 2:998–1004.
   PubMed Web of Science ®Google Scholar
• POLI V, BALENA R, FATTORI E et al: Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J (1994) 13:1189–1196.
   PubMed Web of Science ®Google Scholar
• JOHNSON RB, GILBERT JA, COOPER RC et al.: Alveolar bone loss one year following ovariectomy in sheep. J. Periodontol. (1997) 68:864–871.
   PubMed Web of Science ®Google Scholar
• GALIEN R, GARCIA T: Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-kappaB site. Nucleic Acids Res. (1997) 25:2424–2429.
   PubMed Web of Science ®Google Scholar
• STEIN B, YANG MX: Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol. Cell Biol. (1995) 15:4971–4979.
   PubMed Web of Science ®Google Scholar
• LIN SC, YAMATE T, TAGUCHI Y et al.: Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow. J. Clin. Invest. (1997) 100:1980–1990.
   PubMed Web of Science ®Google Scholar
• ADEBANJO OA, MOONGA BS, YAMATE T et al.: Mode of action of interleukin-6 on mature osteoclasts. Novel interactions with extracellular Ca2+ sensing in the regulation of osteoclastic bone resorption. J. Cell Biol. (1998) 142:1347–1356.
   Google Scholar
• BELLIDO T, O'BRIEN CA, ROBERSON PK, MANOLAGAS SC: Transcriptional activation of the p21(WAF1,CIP1,SDI1) gene by interleukin-6 type cytokines. A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells. J. Biol. Chem. (1998) 273:21137–21144.
   Google Scholar
• JILKA RL, WEINSTEIN RS, BELLIDO T, PARFITT AM, MANOLAGAS SC: Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J. Bone Miner Res. (1998) 13:793–802.
   PubMed Web of Science ®Google Scholar
• KAWASAKI K, GAO YH, YOKOSE S et al.: Osteoclasts are present in gp130-deficient mice. Endocrinology (1997) 138:4959–4965.
   PubMed Web of Science ®Google Scholar
• MARTIN TJ, ROMAS E, GILLESPIE MT: Interleukins in the control of osteoclast differentiation. Grit. Rev. Eukalyot. Gene Expr. (1998) 8:107–123.
   PubMed Web of Science ®Google Scholar
• UDAGAWA N, HORWOOD NJ, ELLIOTT J et al.: Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulo-cyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. J. Exp. Med. (1997) 185:1005–1012.
   PubMed Web of Science ®Google Scholar
• YASUDA H, SHIMA N, NAKAGAWA N et al.: Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/ RANKL. Proc. Natl. Acad. Sci. USA (1998) 95:3597–3602.
   PubMed Web of Science ®Google Scholar
• TREON SP, ANDERSON KC: Interleukin-6 in multiple myeloma and related plasma cell dyscrasias. Curr. Opin. Hematol. (1998) 5:42–48.
   PubMedGoogle Scholar
• SEYMOUR JF, TALPAZ M, HAGEMEISTER FB, CABANILLAS F, KURZROCK R: Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease. Am. J. Med. (1997) 102:21–28.
   PubMed Web of Science ®Google Scholar
• VAN ZAANEN HC, LOKHORST HM, AARDEN LA et al.: Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a Phase I dose-escalating study. Br. J. Haematol. (1998) 102:783–790.
   PubMed Web of Science ®Google Scholar
• SHINKURA H, IMAZEKI I, YAMAZAKI M, ODA Y, KOTOH M, MIHARA M: In vivo blocking effects of a humanized antibody to human interleukin-6 receptor on interleukin-6 function in primates. AntiCancer Res. (1998) 18:1217–1221.
   PubMed Web of Science ®Google Scholar
• SAGGIO I, CIAPPONI L, SAVINO R, CILIBERTO G, PERRICAUDET M: Adenovirus-mediated gene transfer of a human IL-6 antagonist. Gene Ther. (1997) 4:839–845.
   PubMed Web of Science ®Google Scholar
• CIAPPONI L, MAIONE D, SCOUMANNE A et al.: Induction of interleukin-6 (11-6) autoantibodies through vaccina-tion with an engineered 11-6 receptor antagonist. Nature Biotechnol. (1997) 15:997–1001.
   PubMed Web of Science ®Google Scholar
• ••Transfers the principle of generating anti-idiotypicantibodies to cytokines.
   Google Scholar
• XU FH, SHARMA S, GARDNER A et al.: Interleukin-6-induced inhibition of multiple myeloma cell apoptosis: support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway. Blood (1998) 92:241–251.
   PubMed Web of Science ®Google Scholar
• CHAUHAN D, KHARBANDA S, OGATA A et al.: Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood (1997) 89:227–234.
   PubMed Web of Science ®Google Scholar
• CATLETT-FALCONE R, LANDOWSKI TH, OSHIRO MM et al: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity (1999) 10:105–115.
   PubMed Web of Science ®Google Scholar
• •A good reference to start reading into anti-apoptotic effects that depend on STAT3 activation.
   Google Scholar
• OGATA A, CHAUHAN D, TEOH G et al.: IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J. Immunol. (1997) 159:2212–2221.
   PubMed Web of Science ®Google Scholar
• RETTIG MB, MA HJ, VESCIO RA et al: Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science (1997) 276:1851–1854.
   PubMed Web of Science ®Google Scholar
• GAO SJ, ALSINA M, DENG JH et al.: Antibodies to Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in patients with multiple myeloma. J. Infect. Dis. (1998) 178:846–849.
   PubMed Web of Science ®Google Scholar
• BERENSON JR, VESCIO RA: Controversies in haematology: HHV-8 is present in multiple myeloma patients. Blood (1999) 93:3157–3166.
   PubMed Web of Science ®Google Scholar
• TARTE K, CHANG Y, KLEIN B: Controversies in haematology: Kaposi's sarcoma-associated herpes-virus and multiple myeloma- lack of criteris for causality. Blood (1999) 93:3157–3166.
   PubMedGoogle Scholar
• •This and the preceding reference summarize the different views on a potential involvement of KHSV in the genesis of multiple myeloma.
   Google Scholar
• BÉLEC L, MOHAMED AS, AUTHIER F-J et al.: Human herpesvirus-8 infections in patients with POEMs-syndrome associated multicentric Castleman's disease. Blood (1999) 93:3643–3653.
   PubMed Web of Science ®Google Scholar
• FOREMAN KE, BACON PE, HSI ED, NICKOLOFF BJ. In situ polymerase chain reaction-baesd localization studies support role of human herpesvirus-8 as the cause of two AIDS-realted neoplasms: Kaposi's sarcoma and body cavity lyphoma. J. Clin. Inv. (1997) 99:2971–2978.
   PubMed Web of Science ®Google Scholar
• NEIPEL F, ALBRECHT JC, ENSSER A et al.: Human herpes-virus 8 encodes a homolog of interleukin-6. J. Vim]. (1997) 71:839–842.
   Web of Science ®Google Scholar
• NICHOLAS J, RUVOLO VR, BURNS WH et al.: Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nature Med. (1997) 3:287–292.
   PubMed Web of Science ®Google Scholar
• SARID R, SATO T, BOHENZKY RA, RUSSO JJ, CHANG Y: Kaposi's sarcoma-associated herpesvirus encodes a functional bc1-2 homologue. Nature Med. (1997) 3:293–298.
   PubMed Web of Science ®Google Scholar
• MOLDEN J, CHANG Y, YOU Y, MOORE PS, GOLDSMITH MA: A Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J. Biol. Chem. (1997) 272:19625–19631.
   PubMed Web of Science ®Google Scholar
• BURGER R, NEIPEL F, FLECKENSTEIN B et al.: Human herpesvirus Type 8 interleukin-6 homologue is functionally active on human myeloma cells. Blood (1998) 91: 1858-1863.
   Google Scholar
• SCHIRMACHER P, PETERS M, CILIBERTO G et al.: Hepato-cellular hyperplasia, plasmacytoma formation, and extracellular hematopoiesis in interleukin (IL)-6/soluble 11-6 receptor double-transgenic mice. Am. J. Pathol. (1998) 153:639–648.
   PubMed Web of Science ®Google Scholar
• AOKI Y, JAFFE ES, CHANG Y et al.: Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood (1999) 93:4034–4043.
   PubMed Web of Science ®Google Scholar
• ••A very important paper demonstrating that viral IL-6 cancause haematopoiesis, plasmocytosis and increased tumour vascularization in vivo
   Google Scholar
• MESRI E: Inflammatory reactivation and angiogenicity of Kaposi's sarcoma-associated herpesvirus/HHV8: a missing link in the pathogenesis of acquired immuno-deficiency syndrome associated Kaposi's sarcoma. Blood (1999) 93:4031–4033.
   PubMed Web of Science ®Google Scholar
• •An interesting analysis of KHSV related pathology.
   Google Scholar
• COHEN T, NAHARI D, CEREM LW, NEUFELD G, LEVI BZ: Interleukin 6 induces the expression of vascular endothelial growth factor. J. Biol. Chem. (1996) 271:736–741.
   PubMed Web of Science ®Google Scholar
• •Shows that IL-6 has angiogenic potency by inducing VEGF expression.
   Google Scholar
• SITAS F, CARPARA H, BERAL V et al.: Antibodies against human herpesvirus 8 in black south african patients with cancer. New Engl. J. Med. (1999) 340:1863–1871.
   PubMed Web of Science ®Google Scholar
• •First paper to establish an epidemiological link between KHSV infections and Kaposi's sarcoma
   Google Scholar
• OKAMOTO M, LEE C, OYASU R: Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res. (1997) 57:141–146.
   PubMed Web of Science ®Google Scholar
• QIU Y, RAVI L, KUNG HJ: Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature (1998) 393:83–85.
   PubMed Web of Science ®Google Scholar
• QIU Y, ROBINSON D, PRETLOW TG, KUNG H-J: Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3 --kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc. Natl. Acad. Sci. USA (1998) 95:3644–3649.
   PubMed Web of Science ®Google Scholar
• HOBISCH A, EDER i.e. PUTZ T et al.: Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. (1998) 58:4640–4645.
   Google Scholar
• BORSELLINO N, BONAVIDA B, CILIBERTO G, TONIATTI C, TRAVALI S, D'ALESSANDRO N: Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer (1999) 85:134–44.
   PubMed Web of Science ®Google Scholar
• •180–182: A series of good papers that strongly suggest an IL-6 involvement in prostate carcinoma.
   Google Scholar
• LEE Y, PARK US, CHOI I, YOON SK, PARK YM, LEE YI: Human interleukin 6 gene is activated by hepatitis B virus-X protein in human hepatoma cells. Clin. Cancer Res. (1998) 4:1711–1717.
   PubMed Web of Science ®Google Scholar
• ZHU M, PADDOCK GV: Expression of the hepatocyte growth factor-like protein gene in human hepatocel-lular carcinoma and interleukin-6-induced increased expression in hepatoma cells. Biochim. Biophys. Acta. (1999) 1449:63–72.
   PubMed Web of Science ®Google Scholar
• REICHNER JS, MULLIGAN JA, SPISNI R, SOTOMAYOR EA, ALBINA JE, BLAND KI: Effect of IL-6 overexpression on the metastatic potential of rat hepatocellular carcinoma cells. Ann. Surg. Oncol. (1998) 5:279–286.
   PubMed Web of Science ®Google Scholar
• OBATA NH, TAMAKOSHI K, SHIBATA K, KIKKAWA F, TOMODA Y: Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. AntiCancer Res. (1997) 17:337–342.
   PubMed Web of Science ®Google Scholar
• SCHAPER F, SIEWERT E, GOMEZ LECHON MJ et al: Hepatocyte growth factor/scatter factor (HGF/SF) signals via the STAT3/APRF transcription factor in human hepatoma cells and hepatocytes. FEBS Lett. (1997) 405:99–103.
   PubMed Web of Science ®Google Scholar
• OKAMOTO M, HATTORI K, OYASU R: Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int. J. Cancer (1997) 72:149–154.
   PubMed Web of Science ®Google Scholar
• BIHL M, TAMM M, NAUCK M, WIELAND H, PERRUCHOUD AP, ROTH M: Proliferation of human non-small-cell lung cancer cell lines: role of interleukin-6. Am. J. Respir. Cell Mol. Biol. (1998) 19:606–612.
   PubMed Web of Science ®Google Scholar
• CHIU JJ, SGAGIAS MK, COWAN KH: Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines. Clin. Cancer Res. (1996) 2:215–21.
   PubMed Web of Science ®Google Scholar
• ZHANG GJ, ADACHI I: Serum levels of soluble intercel-lular adhesion molecule-1 and E-selectin in metastatic breast carcinoma: correlations with clinicopa-thological features and prognosis. Int. J. Oncol. (1999) 14:71–77.
   PubMed Web of Science ®Google Scholar
• SCOTT HR, MCMILLAN DC, CRILLY A, MCARDLE CS, MILROY R: The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br. J. Cancer. (1996) 73:1560–1562.
   PubMed Web of Science ®Google Scholar
• OKA M, YAMAMOTO K, TAKAHASHI M et al.: Relation-ship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res. (1996) 56:2776–2780.
   PubMed Web of Science ®Google Scholar
• BLAY JY, ROSSI JF, WIJDENES J et al.: Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int. J. Cancer (1997) 72:424–430.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO T, FUJIMOTO-OUCHI K, TAMURA S, TANAKA Y, ISHITSUKA H: Tumour inoculation site-dependent induction of cachexia in mice bearing colon 26 carcinoma. Br. J Cancer (1999) 79:764–769.
   PubMed Web of Science ®Google Scholar
• NAGAI Y, YAMATO H, AKAOGI K et al. Role of interleukin-6 in uncoupling of bone in vivo in a human squamous carcinoma coproducing parathyroid hormone-related peptide and interleukin-6. J. Bone Miner Res. (1998) 13:664–672.
   PubMed Web of Science ®Google Scholar
• MORIYAMA K, WILLIAMS PJ, NIEWOLNA M et al.: Herbimycin A, a tyrosine kinase inhibitor, impairs hypercalcemia associated with a human squamous cancer producing interleukin-6 in nude mice. J. Bone Miner Res. (1996) 11:905–911.
   PubMed Web of Science ®Google Scholar
• PAULE B, CLERC D, RUDANT C et al: Enhanced expres-sion of interleukin-6 in bone and serum of metastatic renal cell carcinoma. Hum. Pathol. (1998) 29:421–424.
   PubMed Web of Science ®Google Scholar
• GIULIANI N, PEDRAZZONI M, PASSERI G, GIRASOLE G: Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand. J. Rheumatol (1998) 27:38–41.
   PubMed Web of Science ®Google Scholar
• BERENSON JR, LICHTENSTEIN A, PORTER L et al.: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J. Oncol. (1998) 16:593–602.
   Google Scholar
• DHODAPKAR MV, SINGH J, MEHTA J et al: Anti-myeloma activity of pamidronate in vivo. Br. J. Haematol. (1998) 103:530–532.
   PubMed Web of Science ®Google Scholar
• ••Two papers that reveal an antimyeloma effect of pamidro-mate that prolongs survival of these patients.
   Google Scholar
• SCHULER M, BRUNTSCH U, SPATH SCHWALBE E et al.: Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: results of a Phase II study. Eur. J. Cancer (1998) 34:754–756.
   Google Scholar
• KATZ A, CHEBATH J, FIEDMAN J, REVEL M: Higher sensitivitiy of IL-6 deficient mice to chemical oxidative hepatotoxicity and in vivo protection by an IL-6 receptot-IL-6 chimera. Eur. Cytokine Netw. (1998) 9:329 (Abstract).
   Google Scholar
• MACKIEWICZ A, ROSE-JOHN S: More about genetically modified tumour vaccines. Gene Therapy (1998) 5:147–148.
   PubMed Web of Science ®Google Scholar
• CHANDRASEKAR B, COLSTON JT, FREEMAN GL: Induction of proinflammatory cytokine and antioxi-dant enzyme gene expression following brief myocar-dial ischaemia. Clin. Exp. Immunol. (1997) 108:346–351.
   PubMed Web of Science ®Google Scholar
• GWECHENBERGER M, MENDOZA LH, YOUKER KA et al.: Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation (1999) 99:546–551.
   PubMed Web of Science ®Google Scholar
• SAWA Y, ICHIKAWA H, KAGISAKI K, OHATA T, MATSUDA H: Interleukin-6 derived from hypoxic myocytes promotes neutrophil-mediated reperfusion injury in myocardium. J. Thorac. Cardiovasc. Surg. (1998) 116:511–517.
   PubMed Web of Science ®Google Scholar
• LIUZZO G, BIASUCCI LM, GALLIMORE JR et al.: The prognostic value of c-reactive protein and serum amyloid a protein in severe unsTable angina. NewEngl. J. Med. (1994) 331:417–424.
   PubMed Web of Science ®Google Scholar
• FRANGOGIANNIS NG, LINDSEY ML, MICHAEL LH et al. Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfu-sion. Circulation (1998) 98:699–710.
   PubMed Web of Science ®Google Scholar
• CHANDRASEKAR B, MITCHELL DH, COLSTON JT, FREEMAN GL: Regulation of CCAAT/Enhancer binding protein, interleukin-6, interleukin-6 receptor, and gp 130expressionduringmyocardialischemia/reperfusion. Circulation (1999) 99:427–433.
   PubMed Web of Science ®Google Scholar
• CHANDRASEKAR B, STREITMAN JE, COLSTON JT, FREEMAN GL: Inhibition of nuclear factor kappa B attenuates proinflammatory cytokine and inducible nitric-oxide synthase expression in postischemic myocardium. Biochim. Biophys. Acta (1998) 1406:91–106.
   PubMed Web of Science ®Google Scholar
• YAO YM, BAHRAMI S, REDL H, FUERST S, SCHLAG G: IL-6 release after intestinal ischemia/reperfusion in rats is under partial control of TNF. j Surg. Res. (1997) 70:21–26.
   PubMed Web of Science ®Google Scholar
• BATHE OF, CHOW AW, PHANG PT: Splanchnic origin of cytokines in a porcine model of mesenteric ischemia-reperfusion. Surgery (1998) 123:79–88.
   PubMed Web of Science ®Google Scholar
• CUZZOCREA S, DE SARRO GB, COSTANTINO G, CILIBERTO G, DE SARRO A, CAPUTI AP: Role of IL-6 in splanchnic artery occlusion shock. Eur. Cytokine Netw. (1998) 9:330 (Abstr).
   Google Scholar
• CHUN TW, ENGEL D, MIZELL SB, EHLER LA, FAUCI AS: Induction of 11IV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J. Exp. Med. (1998) 188:83–91.
   PubMed Web of Science ®Google Scholar
• SHAPIRO L, PUREN AJ, BARTON HA et al.: Interleukin 18 stimulates HIV Type 1 in monocytic cells. Proc. Natl. Acad. ScL USA (1998) 95:12550–12555.
   PubMed Web of Science ®Google Scholar
• ZHANG L, RAMRATNAM B, TENNER-RACZ K et al.: Quanti-fying residual 11IV-1 replication in patients receiving combination antiretroviral therapy. New Engl. J. Med. (1999) 340:1605–1613.
   PubMed Web of Science ®Google Scholar
• FURTADO MR, DUNCAN SC, PHAIR JP et al.: Persistence of 11IV-1 transcription in peripheral-blood mononu-clear cells in patients receiving potent antiretroviral therapy. New Engl. J. Med. (1999) 340:1614–1622.
   PubMed Web of Science ®Google Scholar
• POMERANTZ RJ: Residual 11IV-1 disease in the era of highly active antiretroviral therapy. New Engl. J. Merl. (1999) 340:1672–1675.
   PubMed Web of Science ®Google Scholar
• CHUN T-W, ENGEL D, MIZELL SB et al.: Effect of Interleukin-2 on the pool of latently infected, rested CD4+ T cells in 11IV-1-infected patients receiving highly active anti-retroviral therapy. Nature. Med. (1999) 5.
   PubMedGoogle Scholar
• ••Demonstrates in a clinical trial that cytokines IL-2, IL-6 andTNF-a combined with highly active antiretroviral therapy might further reduce resident HIV-pools in CD4+ T-cells.
   Google Scholar
• MOFFATT S, TANAKA N, TADA K et al.: A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. J. Vim]. (1996) 70:8485–8491.
   Web of Science ®Google Scholar
• CARLQUIST JF EL, BENNION DW, ANDERSON JL: Cytomegalovirus induction of interleukin-6 in lung fibroblasts occurs independently of active infection and involves a G protein and the transcription factor, NF-kappaB. J. Infect. Dis. (1999) 179:1094–1100.
   PubMed Web of Science ®Google Scholar
• GIRES O, KOHLHUBER F, KILGER E et al.: Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT protein. EMBO J (1999) 18:3064–3073.
   PubMed Web of Science ®Google Scholar
• SIMPSON RW, MCGINTY L, SIMON L: Association of parvoviruses with rheumatoid arthritis of humans. Science (1984) 223:1425–1428.
   PubMed Web of Science ®Google Scholar
• NOCTON JJ, MILLER LC, TUCKER LB, SCHALLER JG: Human parvovirus B19-associated arthritis in children. J. Pediatr. (1993) 122:186–190.
   PubMed Web of Science ®Google Scholar
• CORMAN LC, DOLSON DJ: Polyarteritis nodosa and parvovirus B19 infection [letter]. Lancet (1992) 339:491.
   PubMed Web of Science ®Google Scholar
• MEE AP: Paramyxoviruses and Paget's disease: the affirmative view. Bone (1999) 24:19S–21S.
   Google Scholar
• CRESSMAN DE, GREENBAUM LE, DEANGELIS RA et al.: Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science (1996) 274:1379–1383.
   PubMed Web of Science ®Google Scholar
• PETERS M, BLINN G, FISHCER M, SCHIRMACHER P, ROSE-JOHN S: The gp130 activating designer cytokine 'Hyper-IL-6' accelerates liver regeneration. Eur. Cytokine Netw. (1998) 9:329 (Abstr).
   Google Scholar
• SUI Y, TSUJI K, EBIHARA Y et al.: Soluble interleukin 6 (IL-6) receptor with IL-6 stimulates megakaryopoiesis from human CD34+ cells through glycoprotein (gp) 130 signalling. Blood (1999) 93:2525–2532.
   PubMed Web of Science ®Google Scholar
• ISAACS C, ROBERT NJ, BAILEY FA et al.: Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. j Clin. Oncol. (1997) 15:3368–3377.
   PubMed Web of Science ®Google Scholar
• KOLLET O, AVIRAM R, CHEBATH J et al.: The soluble interleukin-6 (IL-6) receptor/IL-6 fusion protein enhances in vitro maintenance and proliferation of human CD34±/ CD3811' cells capable of repopulating severe combined immunodefeciency mice. Blood (1999) Aug1:94(3):923–931.
   Google Scholar
• TAJIMA S, TSUJI K, EBIHARA Y et al.: Analysis of interleukin 6 receptor and gp130 expressions and proliferative capability of human CD34+ cells. J. Exp. Med. (1996) 184:1357–1364.
   PubMed Web of Science ®Google Scholar
• MCKINSTRY WJ, LI CL, RASKO JE, NICOLA NA, JOHNSON GR, METCALF D: Cytokine receptor expression on hematopoietic stem and progenitor cells. Blood (1997) 89:65–71.
   PubMed Web of Science ®Google Scholar
• YOSHIDA K, TAGA T, SAITO M et al: Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc. Natl. Acad. ScL USA (1996) 93:407–411.
   PubMed Web of Science ®Google Scholar
• BETZ UAK, BLOCH W, VAN DEN BROEK M et al.: Postna-tally induced inactivation of gp130 in mice results in neurological, cardiac, hematopoietic, immunological, hepatic, and pulmonary defects. J. Exp. Med. (1998) 188:1955–1965.
   Google Scholar
• ••An unusually thorough study of conditional gp130 / mice. Agood start to read into gp130 dependent biological effects.
   Google Scholar
• CICHY J, ROSE JOHN S, TRAVIS J: Oncostatin M, leukaemia-inhibitory factor and interleukin 6 trigger different effects on alphal-proteinase inhibitor synthesis in human lung-derived epithelial cells. Biochem. J. (1998) 329:335–339.
   PubMed Web of Science ®Google Scholar
• HIROTA H, CHEN J, BETZ UA et al.: Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell (1999) 97:189–198.
   PubMed Web of Science ®Google Scholar
• ••A landmark study. Shows that cardiospecific gp130knock-out does not result in cardiac abnormalities under physiological conditions, despite a strong cardiac phenotype in conditional complete gp130 / mice.
   Google Scholar
• HIROTA, H, YOSHIDA K, KISHIMOTO T, TAGA T: Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc. Natl. Acad. Sci. USA (1995) 92:4862–4866.
   PubMed Web of Science ®Google Scholar
• SHENG Z, PENNICA D, WOOD WI, CHIEN KR: Cardiotrophin-1 displays early expression in the murine heart tube and promotes cardiac myocyte survival. Development (1996) 122:419–428.
   PubMed Web of Science ®Google Scholar
• SHENG Z, KNOWLON K, CHEN J, HOSHIJIMA M, BROWN JH, CHIEN KR: Cardiotrophin-1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. J. Biol. Chem. (1997) 272:5783–5791.
   PubMed Web of Science ®Google Scholar
• OLIVETTI G, ABBI R, QUAINI F et al.: Apoptosis in the failing human heart. New Engl. J. Med. (1997) 336:1131–1141.
   PubMed Web of Science ®Google Scholar
• AUKRUST P, UELAND T, LIEN E et al.: Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. (1999) 83:376–382.
   PubMed Web of Science ®Google Scholar
• MeLLER-NEWEN G, KeSTER A, HEMMANN U et al.: Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. J. Immunol. (1998) 161:6347–6355.
   PubMed Web of Science ®Google Scholar
• •A good study showing that plasma soluble gp130 is able to neutralise IL-6 in the presence of the soluble IL-6 receptor.
   Google Scholar
• KUKIELKA GL, YOUKER KA, HAWKINS HK et al.: Regula-tion of ICAM-1 and IL-6 in myocardial ischemia: effect of reperfusion. Ann. NY Acad. ScL (1994) 723:258–70.
   PubMed Web of Science ®Google Scholar
• KUROKOUCHI K, KAMBE F, YASUKAWA K et al: TNF-alpha increases expression of IL-6 and ICAM-1 genes through activation of NF-kappaB in osteoblast-like ROS17/2.8 cells. J. Bone Miner Res. (1998) 13:1290–1299.
   Google Scholar
• KOPF M, BAUMANN H, FREER G et al.: Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature (1994) 368:339–342.
   PubMed Web of Science ®Google Scholar
• TAKEMOTO S, MULLOY JC, CERESETO A et al.: Prolifera-tion of adult T cell leukemia/ lymphomacells is associ-ated with the constitutive activation of JAK/STAT proteins. Proc. Natl. Acad. ScL USA (1997) 94:13897–13902.
   PubMed Web of Science ®Google Scholar
• WEBER NORDT RM, EGEN C, WEHINGER J et al.: Constitu-tive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood (1996) 88:809–816.
   PubMed Web of Science ®Google Scholar
• TURKSON J, BOWMAN T, GARCIA R et al: Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell Biol. (1998) 18:2545–2552.
   PubMed Web of Science ®Google Scholar
• ALONZI T, GORGONI B, SCREPANTI I eta].: Interleukin-6 and CAAT/enhancer binding protein beta-deficient mice act as tools to dissect the IL-6 signalling pathway and IL-6 regulation. Immunobiology (1997) (198:144–156.
   Google Scholar
• DE BENEDETTI F, MASSA M, PIGNATTI P et al.: Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheuma-toid arthritis. J. Clin. Invest. (1994) 93:2114–2119.
   PubMed Web of Science ®Google Scholar
• DE BENEDETTI F, ALONZI T, MORETTA A et al.: Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J. Clin. Invest. (1997) 99:643–650.
   Google Scholar
• KLEIN B, ZHANG XG LU ZY et al.: Interleukin-6 in human multiple myeloma. Blood (1995) 85:863–872.
   Google Scholar